Photocure ASA

Photocure ASA is a Norwegian specialty pharmaceutical company dedicated to developing and commercializing pharmaceuticals and medical devices based on proprietary photodynamic technology. The company's core mission is to deliver transformative solutions that improve the lives of bladder cancer patients. Headquartered in Oslo, Norway, Photocure operates globally with a focus on the uro-oncology market.

Photocure's primary products are Hexvix® (marketed in Europe) and Cysview® (marketed in the U.S. and Canada), which are used for the detection and management of non-muscle-invasive bladder cancer (NMIBC). These products utilize blue light cystoscopy (BLC) to make cancer cells glow, aiding urologists in better detecting and removing lesions. The company's activities are segmented into a Commercial Franchise, focusing on Hexvix and Cysview, and a Development Portfolio.

Dan Schneider serves as the President and CEO of Photocure. The company continues to expand its market presence, reporting Hexvix®/Cysview® revenues of NOK 135.1 million in the fourth quarter of 2025 and projecting product revenue growth between 7% and 11% for 2026. Recent initiatives include the installation of new Saphira towers in the U.S. and Olympus Visera Elite III systems in Europe to expand BLC use. Photocure is also involved in developing 4K LED high-definition reusable flexible blue light cystoscopes and maintains strategic partnerships to enhance its offerings and market reach.